News
CMMB
1.260
+2.44%
0.030
Weekly Report: what happened at CMMB last week (0505-0509)?
Weekly Report · 1h ago
Chemomab Therapeutics: Promising Phase 2 Data and Attractive Entry Point Justify Buy Rating
TipRanks · 5d ago
Chemomab Therapeutics announces presentation of Phase 2 data of CM-101
TipRanks · 05/05 12:11
Chemomab Announces Presentation Of Nebokitug Phase 2 Clinical Data In Primary Sclerosing Cholangitis In Distinguished Plenary Session At DDW 2025
Benzinga · 05/05 12:09
Weekly Report: what happened at CMMB last week (0428-0502)?
Weekly Report · 05/05 11:23
Biotech Alert: Searches spiking for these stocks today
TipRanks · 04/30 16:15
Chemomab Therapeutics reports new clinical data at EASL 2025 on nebokitug
TipRanks · 04/28 12:31
Chemomab Reports Data From Two Study abstracts To Be Presented At Annual Congress of the European Association for the Study of the Liver May 7-10
Benzinga · 04/28 12:02
CHEMOMAB REPORTS NEW POSITIVE CLINICAL DATA AT EASL 2025 SUPPORTING NEBOKITUG’S IMPACT IN PRIMARY SCLEROSING CHOLANGITIS AND RELATED DISEASES
Reuters · 04/28 12:00
Weekly Report: what happened at CMMB last week (0421-0425)?
Weekly Report · 04/28 11:32
Weekly Report: what happened at CMMB last week (0414-0418)?
Weekly Report · 04/21 11:32
Chemomab Announces Key Leadership Changes Amid Successful Trial Completion
TipRanks · 04/15 12:28
Chemomab Therapeutics appoints Weiner as interim CMO, Lawler as CDO
TipRanks · 04/15 12:23
Weekly Report: what happened at CMMB last week (0407-0411)?
Weekly Report · 04/14 11:21
Weekly Report: what happened at CMMB last week (0331-0404)?
Weekly Report · 04/07 11:20
Weekly Report: what happened at CMMB last week (0324-0328)?
Weekly Report · 03/31 11:33
Promising Phase 3 Prospects and Strategic Study Design Justify Buy Rating for Chemomab Therapeutics
TipRanks · 03/28 15:45
Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease
Benzinga · 03/27 19:18
Chemomab’s Nebokitug Shows Promising Phase 2 Results for PSC
TipRanks · 03/27 12:57
Chemomab Therapeutics reports results in nebokitug Phase 2 PSC OLE trial
TipRanks · 03/27 12:41
More
Webull provides a variety of real-time CMMB stock news. You can receive the latest news about Chemomab Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About CMMB
More
Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.